{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:45:39Z","timestamp":1791870339035,"version":"4.3.4"},"reference-count":205,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T00:00:00Z","timestamp":1791763200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031258","name":"UCSI University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031258","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Diabetes Metab Disord"],"DOI":"10.1007\/s40200-026-02110-3","type":"journal-article","created":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:27:49Z","timestamp":1791826069000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The pharmacotherapy for pediatric obesity: insights and challenges from adult weight-loss medications"],"prefix":"10.1007","volume":"25","author":[{"given":"Zhiyu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AbdulRahman","family":"Muthanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"d\u2019Arqom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau Ling","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Cheng","family":"Ho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming Tatt","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,12]]},"reference":[{"key":"2110_CR1","unstructured":"World Obesity Federation. World Obesity Atlas 2025. 2025 [31 Jul. 2025]."},{"issue":"4","key":"2110_CR2","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S2213-8587(22)00033-X","volume":"10","author":"M Kivimaki","year":"2022","unstructured":"Kivimaki M, Strandberg T, Pentti J, et al. Body-mass index and risk of obesity-related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10(4):253\u201363. https:\/\/doi.org\/10.1016\/S2213-8587(22)00033-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2110_CR3","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1016\/S2468-2667(17)30074-9","volume":"2","author":"M Kivimaki","year":"2017","unstructured":"Kivimaki M, Kuosma E, Ferrie JE, et al. Overweight, obesity, and risk of cardiometabolic multimorbidity: pooled analysis of individual-level data for 120 813 adults from 16 cohort studies from the USA and Europe. Lancet Public Health. 2017;2(6):e277\u201385. https:\/\/doi.org\/10.1016\/S2468-2667(17)30074-9.","journal-title":"Lancet Public Health"},{"key":"2110_CR4","doi-asserted-by":"publisher","first-page":"e2021018","DOI":"10.4178\/epih.e2021018","volume":"43","author":"HA Lee","year":"2021","unstructured":"Lee HA, Park H. Comorbidity network analysis related to obesity in middle-aged and older adults: findings from Korean population-based survey data. Epidemiol Health. 2021;43:e2021018. https:\/\/doi.org\/10.4178\/epih.e2021018.","journal-title":"Epidemiol Health"},{"issue":"3","key":"2110_CR5","doi-asserted-by":"publisher","first-page":"e12436","DOI":"10.1111\/cob.12436","volume":"11","author":"CR Madlock-Brown","year":"2021","unstructured":"Madlock-Brown CR, Reynolds RB, Bailey JE. Increases in multimorbidity with weight class in the United States. Clin Obes. 2021;11(3):e12436. https:\/\/doi.org\/10.1111\/cob.12436.","journal-title":"Clin Obes"},{"issue":"2","key":"2110_CR6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/dom.16263","volume":"27","author":"M Bluher","year":"2025","unstructured":"Bluher M. An overview of obesity-related complications: The epidemiological evidence linking body weight and other markers of obesity to adverse health outcomes. Diabetes Obes Metab. 2025;27(2):3\u201319. https:\/\/doi.org\/10.1111\/dom.16263.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2110_CR7","doi-asserted-by":"publisher","first-page":"e490","DOI":"10.1016\/S2468-2667(18)30139-7","volume":"3","author":"ST Nyberg","year":"2018","unstructured":"Nyberg ST, Batty GD, Pentti J, et al. Obesity and loss of disease-free years owing to major non-communicable diseases: a multicohort study. Lancet Public Health. 2018;3(10):e490\u20137. https:\/\/doi.org\/10.1016\/S2468-2667(18)30139-7.","journal-title":"Lancet Public Health"},{"issue":"1","key":"2110_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.7326\/0003-4819-138-1-200301070-00008","volume":"138","author":"A Peeters","year":"2003","unstructured":"Peeters A, Barendregt JJ, Willekens F, et al. Obesity in adulthood and its consequences for life expectancy: a life-table analysis. Ann Intern Med. 2003;138(1):24\u201332. https:\/\/doi.org\/10.7326\/0003-4819-138-1-200301070-00008.","journal-title":"Ann Intern Med"},{"issue":"2","key":"2110_CR9","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1007\/s40200-026-02037-9","volume":"25","author":"MF Ali","year":"2026","unstructured":"Ali MF, Ahmad H, Qadri M, et al. The weight of risk: epidemiological trends in mortality involving cardiac arrest and obesity in the United States (1999\u20132023). J Diabetes Metabolic Disorders. 2026;25(2):236. https:\/\/doi.org\/10.1007\/s40200-026-02037-9.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"10113","key":"2110_CR10","doi-asserted-by":"publisher","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","volume":"390","author":"N. C. D. Risk Factor Collaboration","year":"2017","unstructured":"N. C. D. Risk Factor Collaboration. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults. Lancet. 2017;390(10113):2627\u201342. https:\/\/doi.org\/10.1016\/S0140-6736(17)32129-3","journal-title":"Lancet"},{"issue":"5","key":"2110_CR11","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1515\/jpem-2024-0316","volume":"38","author":"K Hawton","year":"2025","unstructured":"Hawton K, Shirodkar D, Siese T, et al. A recent update on childhood obesity: aetiology, treatment and complications. J Pediatr Endocrinol Metab. 2025;38(5):429\u201341. https:\/\/doi.org\/10.1515\/jpem-2024-0316.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"37","key":"2110_CR12","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.15585\/mmwr.mm7037a3","volume":"70","author":"SJ Lange","year":"2021","unstructured":"Lange SJ, Kompaniyets L, Freedman DS, et al. Longitudinal trends in body mass index before and during the COVID-19 pandemic among persons Aged 2\u201319 years - United States, 2018\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70(37):1278\u201383. https:\/\/doi.org\/10.15585\/mmwr.mm7037a3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2110_CR13","unstructured":"WHO, Obesity. and overweight 2025 [cited 2025 July 31]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight"},{"issue":"2","key":"2110_CR14","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/obr.12334","volume":"17","author":"M Simmonds","year":"2016","unstructured":"Simmonds M, Llewellyn A, Owen CG, et al. Predicting adult obesity from childhood obesity: a systematic review and meta-analysis. Obes Rev. 2016;17(2):95\u2013107. https:\/\/doi.org\/10.1111\/obr.12334.","journal-title":"Obes Rev"},{"issue":"2","key":"2110_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s40200-025-01774-7","volume":"24","author":"E Peprah Osei","year":"2025","unstructured":"Peprah Osei E, Ekpor E, Osei GY, et al. Global prevalence and factors associated with overweight and obesity in children and adolescents with type 1 diabetes: a systematic review and meta-analysis. J Diabetes Metabolic Disorders. 2025;24(2):257. https:\/\/doi.org\/10.1007\/s40200-025-01774-7.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"21","key":"2110_CR16","doi-asserted-by":"publisher","first-page":"4625","DOI":"10.3390\/nu14214625","volume":"14","author":"Q Ma","year":"2022","unstructured":"Ma Q, Chen T, Liu J, et al. Influence of parental and offspring dietary behaviors on the association of overweight and obesity between two generations: results from a cross-sectional analysis of parent-offspring trios in China. Nutrients. 2022;14(21):4625. https:\/\/doi.org\/10.3390\/nu14214625","journal-title":"Nutrients"},{"issue":"5","key":"2110_CR17","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/01.mop.0000172818.87261.ab","volume":"17","author":"WS Agras","year":"2005","unstructured":"Agras WS, Mascola AJ. Risk factors for childhood overweight. Curr Opin Pediatr. 2005;17(5):648\u201352. https:\/\/doi.org\/10.1097\/01.mop.0000172818.87261.ab.","journal-title":"Curr Opin Pediatr"},{"issue":"1","key":"2110_CR18","doi-asserted-by":"publisher","first-page":"10055","DOI":"10.1038\/s41598-022-14433-1","volume":"12","author":"K Lotfi","year":"2022","unstructured":"Lotfi K, Mohammadi S, Mirzaei S, et al. Dietary total, plant and animal protein intake in relation to metabolic health status in overweight and obese adolescents. Sci Rep. 2022;12(1):10055. https:\/\/doi.org\/10.1038\/s41598-022-14433-1.","journal-title":"Sci Rep"},{"issue":"12","key":"2110_CR19","doi-asserted-by":"publisher","first-page":"4321","DOI":"10.3390\/nu13124321","volume":"13","author":"S Stabouli","year":"2021","unstructured":"Stabouli S, Erdine S, Suurorg L, et al. Obesity and eating disorders in children and adolescents: the bidirectional link. Nutrients. 2021;13(12):4321. https:\/\/doi.org\/10.3390\/nu13124321","journal-title":"Nutrients"},{"issue":"6","key":"2110_CR20","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.3390\/nu12061835","volume":"12","author":"V Hruska","year":"2020","unstructured":"Hruska V, Darlington G, Haines J, et al. Parent stress as a consideration in childhood obesity prevention: results from the guelph family health study, a pilot randomized controlled trial. Nutrients. 2020;12(6):1835. https:\/\/doi.org\/10.3390\/nu12061835","journal-title":"Nutrients"},{"issue":"22","key":"2110_CR21","doi-asserted-by":"publisher","first-page":"4736","DOI":"10.3390\/nu15224736","volume":"15","author":"V Calcaterra","year":"2023","unstructured":"Calcaterra V, Rossi V, Tagi VM, et al. Food intake and sleep disorders in children and adolescents with obesity. Nutrients. 2023;15(22):4736. https:\/\/doi.org\/10.3390\/nu15224736","journal-title":"Nutrients"},{"issue":"24","key":"2110_CR22","doi-asserted-by":"publisher","first-page":"16728","DOI":"10.3390\/ijerph192416728","volume":"19","author":"V Calcaterra","year":"2022","unstructured":"Calcaterra V, Marin L, Vandoni M, et al. Childhood obesity and incorrect body posture: impact on physical activity and the therapeutic role of exercise. Int J Environ Res Public Health. 2022;19(24):16728. https:\/\/doi.org\/10.3390\/ijerph192416728","journal-title":"Int J Environ Res Public Health"},{"issue":"17","key":"2110_CR23","doi-asserted-by":"publisher","first-page":"e36835","DOI":"10.1016\/j.heliyon.2024.e36835","volume":"10","author":"J Cai","year":"2024","unstructured":"Cai J, Zhao L, Li N, et al. Mendelian randomization analysis separated the independent impact of childhood obesity and adult obesity on socioeconomic status, psychological status, and substance use. Heliyon. 2024;10(17):e36835. https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36835.","journal-title":"Heliyon"},{"issue":"2","key":"2110_CR24","doi-asserted-by":"publisher","first-page":"e2022060640","DOI":"10.1542\/peds.2022-060640","volume":"151","author":"SE Hampl","year":"2023","unstructured":"Hampl SE, Hassink SG, Skinner AC, et al. Clinical practice guideline for the evaluation and treatment of children and adolescents with obesity. Pediatrics. 2023;151(2):e2022060640. https:\/\/doi.org\/10.1542\/peds.2022-060640","journal-title":"Pediatrics"},{"issue":"20","key":"2110_CR25","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1001\/jama.2023.19897","volume":"330","author":"A Elmaleh-Sachs","year":"2023","unstructured":"Elmaleh-Sachs A, Schwartz JL, Bramante CT, et al. Obesity management in adults: a review. JAMA. 2023;330(20):2000\u201315. https:\/\/doi.org\/10.1001\/jama.2023.19897.","journal-title":"JAMA"},{"key":"2110_CR26","doi-asserted-by":"publisher","first-page":"100113","DOI":"10.1016\/j.obpill.2024.100113","volume":"11","author":"S Cuda","year":"2024","unstructured":"Cuda S, Censani M, O\u2019Hara V, et al. Special considerations for the child with obesity: an Obesity Medicine Association (OMA) clinical practice statement (CPS) 2024. Obes Pillars. 2024;11:100113. https:\/\/doi.org\/10.1016\/j.obpill.2024.100113.","journal-title":"Obes Pillars"},{"issue":"5","key":"2110_CR27","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S2213-8587(22)00047-X","volume":"10","author":"H Jebeile","year":"2022","unstructured":"Jebeile H, Kelly AS, O\u2019Malley G, et al. Obesity in children and adolescents: epidemiology, causes, assessment, and management. Lancet Diabetes Endocrinol. 2022;10(5):351\u201365. https:\/\/doi.org\/10.1016\/S2213-8587(22)00047-X.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2110_CR28","doi-asserted-by":"publisher","first-page":"2","DOI":"10.2174\/1573396318666220801093225","volume":"20","author":"AKC Leung","year":"2024","unstructured":"Leung AKC, Wong AHC, Hon KL. Childhood obesity: an updated review. Curr Pediatr Rev. 2024;20(1):2\u201326. https:\/\/doi.org\/10.2174\/1573396318666220801093225.","journal-title":"Curr Pediatr Rev"},{"issue":"3","key":"2110_CR29","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1007\/s13181-011-0162-6","volume":"7","author":"J Grundlingh","year":"2011","unstructured":"Grundlingh J, Dargan PI, El-Zanfaly M, et al. 2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death. J Med Toxicol. 2011;7(3):205\u201312. https:\/\/doi.org\/10.1007\/s13181-011-0162-6.","journal-title":"J Med Toxicol"},{"issue":"3","key":"2110_CR30","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s10928-022-09806-y","volume":"49","author":"LF Meyer","year":"2022","unstructured":"Meyer LF, Rajadhyaksha PM, Shah DK. Physiologically-based pharmacokinetic model for 2,4-dinitrophenol. J Pharmacokinet Pharmacodyn. 2022;49(3):325\u201336. https:\/\/doi.org\/10.1007\/s10928-022-09806-y.","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"2110_CR31","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1124\/pr.117.014803","volume":"70","author":"TD Muller","year":"2018","unstructured":"Muller TD, Clemmensen C, Finan B, et al. Anti-obesity therapy: from rainbow pills to polyagonists. Pharmacol Rev. 2018;70(4):712\u201346. https:\/\/doi.org\/10.1124\/pr.117.014803.","journal-title":"Pharmacol Rev"},{"issue":"1","key":"2110_CR32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1354\/vp.46-1-10","volume":"46","author":"CS Elangbam","year":"2009","unstructured":"Elangbam CS. Review paper: Current strategies in the development of anti-obesity drugs and their safety concerns. Vet Pathol. 2009;46(1):10\u201324. https:\/\/doi.org\/10.1354\/vp.46-1-10.","journal-title":"Vet Pathol"},{"issue":"10","key":"2110_CR33","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0160-3450(16)33611-X","volume":"NS30","author":"DM Williams","year":"1990","unstructured":"Williams DM. Phenylpropanolamine hydrochloride. Am Pharm. 1990;NS30(10):47\u201350.","journal-title":"Am Pharm"},{"issue":"3","key":"2110_CR34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-021-00337-8","volume":"21","author":"TD Muller","year":"2022","unstructured":"Muller TD, Bluher M, Tschop MH, et al. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21(3):201\u201323. https:\/\/doi.org\/10.1038\/s41573-021-00337-8.","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2110_CR35","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1080\/03007995.2017.1355781","volume":"33","author":"AS Schoonjans","year":"2017","unstructured":"Schoonjans AS, Marchau F, Paelinck BP, et al. Cardiovascular safety of low-dose fenfluramine in Dravet syndrome: a review of its benefit-risk profile in a new patient population. Curr Med Res Opin. 2017;33(10):1773\u201381. https:\/\/doi.org\/10.1080\/03007995.2017.1355781.","journal-title":"Curr Med Res Opin"},{"issue":"5","key":"2110_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1358\/mf.2000.22.5.796647","volume":"22","author":"A Carvajal","year":"2000","unstructured":"Carvajal A, Garcia del Pozo J, Martin de Diego I, et al. Efficacy of fenfluramine and dexfenfluramine in the treatment of obesity: a meta-analysis. Methods Find Exp Clin Pharmacol. 2000;22(5):285\u201390. https:\/\/doi.org\/10.1358\/mf.2000.22.5.796647.","journal-title":"Methods Find Exp Clin Pharmacol"},{"issue":"3","key":"2110_CR37","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1517\/14656566.5.3.633","volume":"5","author":"WS Poston","year":"2004","unstructured":"Poston WS, Foreyt JP. Sibutramine and the management of obesity. Expert Opin Pharmacother. 2004;5(3):633\u2013. https:\/\/doi.org\/10.1517\/14656566.5.3.633. \u200942.","journal-title":"Expert Opin Pharmacother"},{"issue":"1","key":"2110_CR38","doi-asserted-by":"publisher","first-page":"100002","DOI":"10.1124\/pharmrev.123.001045","volume":"77","author":"M Kokkorakis","year":"2025","unstructured":"Kokkorakis M, Chakhtoura M, Rhayem C, et al. Emerging pharmacotherapies for obesity: a systematic review. Pharmacol Rev. 2025;77(1):100002. https:\/\/doi.org\/10.1124\/pharmrev.123.001045.","journal-title":"Pharmacol Rev"},{"key":"2110_CR39","unstructured":"Anvisa. Sibutramina e rem\u00e9dios para emagrecer: entenda 2022. Available from: https:\/\/www.gov.br\/anvisa\/pt-br\/assuntos\/noticias-anvisa\/2018\/sibutramina-e-remedios-para-emagrecer-entenda"},{"issue":"9","key":"2110_CR40","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.2105\/AJPH.2012.300655","volume":"102","author":"PA Cohen","year":"2012","unstructured":"Cohen PA, Goday A, Swann JP. The return of rainbow diet pills. Am J Public Health. 2012;102(9):1676\u201386. https:\/\/doi.org\/10.2105\/AJPH.2012.300655.","journal-title":"Am J Public Health"},{"issue":"3","key":"2110_CR41","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2174\/157489008786264014","volume":"3","author":"A Samat","year":"2008","unstructured":"Samat A, Tomlinson B, Taheri S, et al. Rimonabant for the treatment of obesity. Recent Pat Cardiovasc Drug Discov. 2008;3(3):187\u201393. https:\/\/doi.org\/10.2174\/157489008786264014.","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"issue":"Suppl 2","key":"2110_CR42","doi-asserted-by":"publisher","first-page":"S229","DOI":"10.2337\/dc08-s258","volume":"31","author":"L Van Gaal","year":"2008","unstructured":"Van Gaal L, Pi-Sunyer X, Despres JP, et al. Efficacy and safety of rimonabant for improvement of multiple cardiometabolic risk factors in overweight\/obese patients: pooled 1-year data from the Rimonabant in Obesity (RIO) program. Diabetes Care. 2008;31(Suppl 2):S229\u201340. https:\/\/doi.org\/10.2337\/dc08-s258.","journal-title":"Diabetes Care"},{"issue":"7","key":"2110_CR43","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1002\/oby.24019","volume":"32","author":"Y Cohen","year":"2024","unstructured":"Cohen Y, Kolodziej A, Morningstar M. Seventeen years since rimonabant\u2019s downfall: reassessing its suicidality risk profile. Obes (Silver Spring). 2024;32(7):1235\u201344. https:\/\/doi.org\/10.1002\/oby.24019.","journal-title":"Obes (Silver Spring)"},{"issue":"3","key":"2110_CR44","doi-asserted-by":"publisher","first-page":"278","DOI":"10.2174\/1871527322666230330124137","volume":"23","author":"M Mazza","year":"2024","unstructured":"Mazza M, Kotzalidis GD, Marano G, et al. Lorcaserin: worthy of further insights? Results from recent research. CNS Neurol Disord Drug Targets. 2024;23(3):278\u201383. https:\/\/doi.org\/10.2174\/1871527322666230330124137.","journal-title":"CNS Neurol Disord Drug Targets"},{"issue":"7","key":"2110_CR45","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1002\/oby.22789","volume":"28","author":"R Kumar","year":"2020","unstructured":"Kumar R, Ryan D. Lorcaserin Departs, Leaving More Questions than Answers. Obes (Silver Spring). 2020;28(7):1167. https:\/\/doi.org\/10.1002\/oby.22789.","journal-title":"Obes (Silver Spring)"},{"issue":"3","key":"2110_CR46","doi-asserted-by":"publisher","first-page":"e13170","DOI":"10.1111\/obr.13170","volume":"22","author":"L de Andrade Mesquita","year":"2021","unstructured":"de Andrade Mesquita L, Fagundes Piccoli G, Richter da Natividade G, et al. Is lorcaserin really associated with increased risk of cancer? A systematic review and meta-analysis. Obes Rev. 2021;22(3):e13170. https:\/\/doi.org\/10.1111\/obr.13170.","journal-title":"Obes Rev"},{"issue":"2","key":"2110_CR47","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1080\/17512433.2020.1703109","volume":"13","author":"AK Singh","year":"2020","unstructured":"Singh AK, Singh R. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. Expert Rev Clin Pharmacol. 2020;13(2):183\u201390. https:\/\/doi.org\/10.1080\/17512433.2020.1703109.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"5","key":"2110_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.6061\/clinics\/2017(05)10","volume":"72","author":"RC Lucchetta","year":"2017","unstructured":"Lucchetta RC, Riveros BS, Pontarolo R, et al. Systematic review and meta-analysis of the efficacy and safety of amfepramone and mazindol as a monotherapy for the treatment of obese or overweight patients. Clin (Sao Paulo). 2017;72(5):317\u201324. https:\/\/doi.org\/10.6061\/clinics\/2017(05)10.","journal-title":"Clin (Sao Paulo)"},{"issue":"17","key":"2110_CR49","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.2174\/156802606778249766","volume":"6","author":"RB Rothman","year":"2006","unstructured":"Rothman RB, Baumann MH. Therapeutic potential of monoamine transporter substrates. Curr Top Med Chem. 2006;6(17):1845\u201359. https:\/\/doi.org\/10.2174\/156802606778249766.","journal-title":"Curr Top Med Chem"},{"key":"2110_CR50","unstructured":"European Medicines Agency. EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines 2022. Available from: https:\/\/www.ema.europa.eu\/en\/news\/ema-confirms-recommendation-withdraw-marketing-authorisations-amfepramone-medicines"},{"issue":"11","key":"2110_CR51","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1002\/oby.20584","volume":"21","author":"LJ Aronne","year":"2013","unstructured":"Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults. Obes (Silver Spring). 2013;21(11):2163\u201371. https:\/\/doi.org\/10.1002\/oby.20584.","journal-title":"Obes (Silver Spring)"},{"issue":"4","key":"2110_CR52","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1159\/000478098","volume":"10","author":"H Hauner","year":"2017","unstructured":"Hauner H, Hastreiter L, Werdier D, et al. Efficacy and safety of cathine (nor-pseudoephedrine) in the treatment of obesity: a randomized dose-finding study. Obes Facts. 2017;10(4):407\u201319. https:\/\/doi.org\/10.1159\/000478098.","journal-title":"Obes Facts"},{"issue":"1","key":"2110_CR53","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1007\/s13679-023-00546-9","volume":"13","author":"KH Lewis","year":"2024","unstructured":"Lewis KH, Gudzune KA, Ard JD. Phentermine in the modern era of obesity pharmacotherapy: does it still have a role in treatment? Curr Obes Rep. 2024;13(1):132\u201340. https:\/\/doi.org\/10.1007\/s13679-023-00546-9.","journal-title":"Curr Obes Rep"},{"issue":"6","key":"2110_CR54","first-page":"363","volume":"17","author":"GA Medeiros-Neto","year":"1993","unstructured":"Medeiros-Neto GA. Should drugs be used for treating obese children? Int J Obes Relat Metab Disord. 1993;17(6):363.","journal-title":"Int J Obes Relat Metab Disord"},{"issue":"1","key":"2110_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/j.1550-8528.1994.tb00036.x","volume":"2","author":"F Pedrinola","year":"1994","unstructured":"Pedrinola F, Cavaliere H, Lima N, et al. Is DL-fenfluramine a potentially helpful drug therapy in overweight adolescent subjects? Obes Res. 1994;2(1):1\u20134. https:\/\/doi.org\/10.1002\/j.1550-8528.1994.tb00036.x.","journal-title":"Obes Res"},{"issue":"11","key":"2110_CR56","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1210\/jc.2007-0826","volume":"92","author":"P Danielsson","year":"2007","unstructured":"Danielsson P, Janson A, Norgren S, et al. Impact sibutramine therapy in children with hypothalamic obesity or obesity with aggravating syndromes. J Clin Endocrinol Metab. 2007;92(11):4101\u20136. https:\/\/doi.org\/10.1210\/jc.2007-0826.","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2110_CR57","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.3390\/life13041012","volume":"13","author":"F Haddad","year":"2023","unstructured":"Haddad F, Dokmak G, Bader M, et al. A comprehensive review on weight loss associated with anti-diabetic medications. Life (Basel). 2023;13(4):1012. https:\/\/doi.org\/10.3390\/life13041012","journal-title":"Life (Basel)"},{"issue":"1","key":"2110_CR58","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s40200-024-01512-5","volume":"24","author":"S Dodangeh","year":"2024","unstructured":"Dodangeh S, Hasani-Ranjbar S. Old and new anti-obesity drugs. J Diabetes Metabolic Disorders. 2024;24(1):16. https:\/\/doi.org\/10.1007\/s40200-024-01512-5.","journal-title":"J Diabetes Metabolic Disorders"},{"key":"2110_CR59","doi-asserted-by":"publisher","first-page":"125","DOI":"10.2147\/AHMT.S383454","volume":"14","author":"A Kim","year":"2023","unstructured":"Kim A, Nguyen J, Babaei M, et al. A narrative review: phentermine and topiramate for the treatment of pediatric obesity. Adolesc Health Med Ther. 2023;14:125\u201340. https:\/\/doi.org\/10.2147\/AHMT.S383454.","journal-title":"Adolesc Health Med Ther"},{"issue":"2","key":"2110_CR60","doi-asserted-by":"publisher","first-page":"127","DOI":"10.23736\/S0391-1977.20.03179-X","volume":"45","author":"L Barrea","year":"2020","unstructured":"Barrea L, Pugliese G, Muscogiuri G, et al. New-generation anti-obesity drugs: naltrexone\/bupropion and liraglutide. An update for endocrinologists and nutritionists. Minerva Endocrinol. 2020;45(2):127\u201337. https:\/\/doi.org\/10.23736\/S0391-1977.20.03179-X.","journal-title":"Minerva Endocrinol"},{"issue":"6","key":"2110_CR61","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1177\/87551225221116010","volume":"38","author":"H Pressley","year":"2022","unstructured":"Pressley H, Cornelio CK, Adams EN. Setmelanotide: a novel targeted treatment for monogenic obesity. J Pharm Technol. 2022;38(6):368\u201373. https:\/\/doi.org\/10.1177\/87551225221116010.","journal-title":"J Pharm Technol"},{"issue":"3","key":"2110_CR62","doi-asserted-by":"publisher","first-page":"196","DOI":"10.7570\/jomes21033","volume":"30","author":"DH Ryan","year":"2021","unstructured":"Ryan DH. Next generation antiobesity medications: setmelanotide, semaglutide, tirzepatide and bimagrumab: what do they mean for clinical practice? J Obes Metab Syndr. 2021;30(3):196\u2013208. https:\/\/doi.org\/10.7570\/jomes21033.","journal-title":"J Obes Metab Syndr"},{"issue":"10","key":"2110_CR63","doi-asserted-by":"publisher","first-page":"101757","DOI":"10.1016\/j.jsps.2023.101757","volume":"31","author":"S Abdi Beshir","year":"2023","unstructured":"Abdi Beshir S, Ahmed Elnour A, Soorya A, et al. A narrative review of approved and emerging anti-obesity medications. Saudi Pharm J. 2023;31(10):101757. https:\/\/doi.org\/10.1016\/j.jsps.2023.101757.","journal-title":"Saudi Pharm J"},{"issue":"1","key":"2110_CR64","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13052-023-01458-z","volume":"49","author":"C Maffeis","year":"2023","unstructured":"Maffeis C, Olivieri F, Valerio G, et al. The treatment of obesity in children and adolescents: consensus position statement of the Italian society of pediatric endocrinology and diabetology, Italian Society of Pediatrics and Italian Society of Pediatric Surgery. Ital J Pediatr. 2023;49(1):69. https:\/\/doi.org\/10.1186\/s13052-023-01458-z.","journal-title":"Ital J Pediatr"},{"key":"2110_CR65","unstructured":"Farzam K, Patel P, Tirzepatide LLC. 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/36251836"},{"issue":"12","key":"2110_CR66","doi-asserted-by":"publisher","first-page":"103382","DOI":"10.1016\/j.isci.2021.103382","volume":"24","author":"F Zhang","year":"2021","unstructured":"Zhang F, Chen Z, Wu D, et al. Recombinant human GLP-1 beinaglutide regulates lipid metabolism of adipose tissues in diet-induced obese mice. iScience. 2021;24(12):103382. https:\/\/doi.org\/10.1016\/j.isci.2021.103382.","journal-title":"iScience"},{"issue":"217","key":"2110_CR67","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/adc.41.217.309","volume":"41","author":"J Lorber","year":"1966","unstructured":"Lorber J. Obesity in childhood. A controlled trial of anorectic drugs. Arch Dis Child. 1966;41(217):309\u2013. https:\/\/doi.org\/10.1136\/adc.41.217.309. \u200912.","journal-title":"Arch Dis Child"},{"issue":"3","key":"2110_CR68","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1002\/oby.23346","volume":"30","author":"JR Ryder","year":"2022","unstructured":"Ryder JR, Kelly AS, Freedman DS. Metrics matter: Toward consensus reporting of BMI and weight-related outcomes in pediatric obesity clinical trials. Obes (Silver Spring). 2022;30(3):571\u20132. https:\/\/doi.org\/10.1002\/oby.23346.","journal-title":"Obes (Silver Spring)"},{"issue":"7","key":"2110_CR69","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1001\/jama.2024.10816","volume":"332","author":"KA Gudzune","year":"2024","unstructured":"Gudzune KA, Kushner RF. Medications for Obesity: A Review. JAMA. 2024;332(7):571\u201384. https:\/\/doi.org\/10.1001\/jama.2024.10816.","journal-title":"JAMA"},{"issue":"9","key":"2110_CR70","doi-asserted-by":"publisher","first-page":"3626","DOI":"10.1007\/s12325-023-02586-y","volume":"40","author":"NZ Pearl","year":"2023","unstructured":"Pearl NZ, Babin CP, Catalano NT, et al. Narrative review of topiramate: clinical uses and pharmacological considerations. Adv Ther. 2023;40(9):3626\u201338. https:\/\/doi.org\/10.1007\/s12325-023-02586-y.","journal-title":"Adv Ther"},{"key":"2110_CR71","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/bs.podrm.2018.11.005","volume":"44","author":"NY Khalil","year":"2019","unstructured":"Khalil NY, AlRabiah HK, Al Rashoud SS, et al. Topiramate: comprehensive profile. Profiles Drug Subst Excip Relat Methodol. 2019;44:333\u201378. https:\/\/doi.org\/10.1016\/bs.podrm.2018.11.005.","journal-title":"Profiles Drug Subst Excip Relat Methodol"},{"issue":"6","key":"2110_CR72","doi-asserted-by":"publisher","first-page":"10.1056\/evidoa2","DOI":"10.1056\/evidoa2200014","volume":"1","author":"AS Kelly","year":"2022","unstructured":"Kelly AS, Bensignor MO, Hsia DS, et al. Phentermine\/topiramate for the treatment of adolescent obesity. NEJM Evid. 2022;1(6). https:\/\/doi.org\/10.1056\/evidoa2200014","journal-title":"NEJM Evid"},{"issue":"6","key":"2110_CR73","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1007\/s40272-022-00532-z","volume":"24","author":"S Dhillon","year":"2022","unstructured":"Dhillon S. Phentermine\/topiramate: pediatric first approval. Paediatr Drugs. 2022;24(6):715\u201320. https:\/\/doi.org\/10.1007\/s40272-022-00532-z.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"2110_CR74","doi-asserted-by":"publisher","first-page":"e12701","DOI":"10.1111\/ijpo.12701","volume":"16","author":"C Borzutzky","year":"2021","unstructured":"Borzutzky C, King E, Fox CK, et al. Trends in prescribing anti-obesity pharmacotherapy for paediatric weight management: data from the POWER Work Group. Pediatr Obes. 2021;16(1):e12701. https:\/\/doi.org\/10.1111\/ijpo.12701.","journal-title":"Pediatr Obes"},{"key":"2110_CR75","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.phrs.2014.04.004","volume":"84","author":"SK Billes","year":"2014","unstructured":"Billes SK, Sinnayah P, Cowley MA. Naltrexone\/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1\u201311. https:\/\/doi.org\/10.1016\/j.phrs.2014.04.004.","journal-title":"Pharmacol Res"},{"key":"2110_CR76","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-025-06873-0","author":"H Alim Ur Rahman","year":"2025","unstructured":"Alim Ur Rahman H, Fahim MAA, Naeem U, et al. The weight reducing effects of naltrexone-bupropion among obese psychiatric and non-psychiatric patients: a systematic review. Psychopharmacology. 2025. https:\/\/doi.org\/10.1007\/s00213-025-06873-0.","journal-title":"Psychopharmacology"},{"issue":"9","key":"2110_CR77","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1586\/14737175.6.9.1249","volume":"6","author":"KF Foley","year":"2006","unstructured":"Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006;6(9):1249\u201365. https:\/\/doi.org\/10.1586\/14737175.6.9.1249.","journal-title":"Expert Rev Neurother"},{"key":"2110_CR78","doi-asserted-by":"publisher","first-page":"111789","DOI":"10.1016\/j.biopha.2021.111789","volume":"140","author":"J Aaseth","year":"2021","unstructured":"Aaseth J, Ellefsen S, Alehagen U, et al. Diets and drugs for weight loss and health in obesity - An update. Biomed Pharmacother. 2021;140:111789. https:\/\/doi.org\/10.1016\/j.biopha.2021.111789.","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"2110_CR79","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1111\/adb.12033","volume":"19","author":"A Blasio","year":"2014","unstructured":"Blasio A, Steardo L, Sabino V, et al. Opioid system in the medial prefrontal cortex mediates binge-like eating. Addict Biol. 2014;19(4):652\u201362. https:\/\/doi.org\/10.1111\/adb.12033.","journal-title":"Addict Biol"},{"issue":"2","key":"2110_CR80","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1007\/s12020-024-04029-2","volume":"87","author":"DTW Lui","year":"2025","unstructured":"Lui DTW, Tsoi KH, Fong CHY, et al. Real-world efficacy and safety of naltrexone-bupropion therapy in Chinese patients with obesity: a single-centre experience. Endocrine. 2025;87(2):522\u20139. https:\/\/doi.org\/10.1007\/s12020-024-04029-2.","journal-title":"Endocrine"},{"issue":"2","key":"2110_CR81","doi-asserted-by":"publisher","first-page":"e12724","DOI":"10.1111\/cob.12724","volume":"15","author":"S Wharton","year":"2025","unstructured":"Wharton S, Kamran E, Thabane L, et al. The real-world relationship between naltrexone\/bupropion treatment and weight loss in Canada: a retrospective chart review. Clin Obes. 2025;15(2):e12724. https:\/\/doi.org\/10.1111\/cob.12724.","journal-title":"Clin Obes"},{"issue":"4","key":"2110_CR82","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1111\/bcp.14210","volume":"86","author":"IJ Onakpoya","year":"2020","unstructured":"Onakpoya IJ, Lee JJ, Mahtani KR, et al. Naltrexone-bupropion (Mysimba) in management of obesity: a systematic review and meta-analysis of unpublished clinical study reports. Br J Clin Pharmacol. 2020;86(4):646\u201367. https:\/\/doi.org\/10.1111\/bcp.14210.","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"2110_CR83","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1097\/01.NAJ.0000925488.72453.63","volume":"123","author":"DS Aschenbrenner","year":"2023","unstructured":"Aschenbrenner DS. New combination drug for depression. Am J Nurs. 2023;123(4):24\u20135. https:\/\/doi.org\/10.1097\/01.NAJ.0000925488.72453.63.","journal-title":"Am J Nurs"},{"key":"2110_CR84","unstructured":"European Medicines Agency, Mysimba. 2025. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/mysimba"},{"key":"2110_CR85","unstructured":"Multum C. Bupropion and naltrexone 2025. Available from: https:\/\/www.drugs.com\/mtm\/bupropion-and-naltrexone.html"},{"issue":"2","key":"2110_CR86","doi-asserted-by":"publisher","first-page":"62","DOI":"10.17925\/EE.2024.20.2.9","volume":"20","author":"S Qamar","year":"2024","unstructured":"Qamar S, Mallik R, Makaronidis J, Setmelanotide. A melanocortin-4 receptor agonist for the treatment of severe obesity due to hypothalamic dysfunction. touchREV Endocrinol. 2024;20(2):62\u201371. https:\/\/doi.org\/10.17925\/EE.2024.20.2.9.","journal-title":"touchREV Endocrinol"},{"issue":"3","key":"2110_CR87","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40265-021-01470-9","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A, Setmelanotide. First Approval Drugs. 2021;81(3):397\u2013403. https:\/\/doi.org\/10.1007\/s40265-021-01470-9.","journal-title":"First Approval Drugs"},{"issue":"8","key":"2110_CR88","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1080\/14740338.2025.2465880","volume":"25","author":"K Sridharan","year":"2026","unstructured":"Sridharan K, Sivaramakrishnan G. Adverse event profile of setmelanotide in obesity: an integrated assessment and systematic review using disproportionality analysis, case reports and meta-analysis. Expert Opin Drug Saf. 2026;25(8):1507\u20131516. https:\/\/doi.org\/10.1080\/14740338.2025.2465880","journal-title":"Expert Opin Drug Saf"},{"issue":"1","key":"2110_CR89","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13023-022-02186-z","volume":"17","author":"P Kuhnen","year":"2022","unstructured":"Kuhnen P, Wabitsch M, von Schnurbein J, et al. Quality of life outcomes in two phase 3 trials of setmelanotide in patients with obesity due to LEPR or POMC deficiency. Orphanet J Rare Dis. 2022;17(1):38. https:\/\/doi.org\/10.1186\/s13023-022-02186-z.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2110_CR90","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.3390\/jpm13101460","volume":"13","author":"Barbosa B Ferraz","year":"2023","unstructured":"Ferraz Barbosa B, Aquino de Moraes FC, Bordignon Barbosa C, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, for obese patients: a systematic review and meta-analysis. J Pers Med. 2023;13(10):1460. https:\/\/doi.org\/10.3390\/jpm13101460","journal-title":"J Pers Med"},{"issue":"12","key":"2110_CR91","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/S2213-8587(22)00277-7","volume":"10","author":"AM Haqq","year":"2022","unstructured":"Haqq AM, Chung WK, Dollfus H, et al. Efficacy and safety of setmelanotide, a melanocortin-4 receptor agonist, in patients with Bardet-Biedl syndrome and Alstrom syndrome: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial with an open-label period. Lancet Diabetes Endocrinol. 2022;10(12):859\u201368. https:\/\/doi.org\/10.1016\/S2213-8587(22)00277-7.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"12","key":"2110_CR92","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/S2213-8587(20)30364-8","volume":"8","author":"K Clement","year":"2020","unstructured":"Clement K, van den Akker E, Argente J, et al. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials. Lancet Diabetes Endocrinol. 2020;8(12):960\u201370. https:\/\/doi.org\/10.1016\/S2213-8587(20)30364-8.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"2110_CR93","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/S2213-8587(24)00273-0","volume":"13","author":"J Argente","year":"2025","unstructured":"Argente J, Verge CF, Okorie U, et al. Setmelanotide in patients aged 2\u20135 years with rare MC4R pathway-associated obesity (VENTURE): a 1 year, open-label, multicenter, phase 3 trial. Lancet Diabetes Endocrinol. 2025;13(1):29\u201337. https:\/\/doi.org\/10.1016\/S2213-8587(24)00273-0.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2110_CR94","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/S2213-8587(24)00087-1","volume":"12","author":"CL Roth","year":"2024","unstructured":"Roth CL, Scimia C, Shoemaker AH, et al. Setmelanotide for the treatment of acquired hypothalamic obesity: a phase 2, open-label, multicentre trial. Lancet Diabetes Endocrinol. 2024;12(6):380\u20139. https:\/\/doi.org\/10.1016\/S2213-8587(24)00087-1.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"Supplement1","key":"2110_CR95","doi-asserted-by":"publisher","first-page":"A37","DOI":"10.1210\/jendso\/bvac150.076","volume":"6","author":"M Wabitsch","year":"2022","unstructured":"Wabitsch M, Farooqi S, Argente J, et al. RF24 | PSUN96 setmelanotide in patients with heterozygous POMC, LEPR, SRC1, or SH2B1 obesity: design of EMANATE \u2013 A placebo-controlled phase 3 trial. J Endocr Soc. 2022;6(Supplement1):A37\u201337. https:\/\/doi.org\/10.1210\/jendso\/bvac150.076.","journal-title":"J Endocr Soc"},{"issue":"3","key":"2110_CR96","doi-asserted-by":"publisher","first-page":"288","DOI":"10.15252\/emmm.201404508","volume":"7","author":"C Clemmensen","year":"2015","unstructured":"Clemmensen C, Finan B, Fischer K, et al. Dual melanocortin-4 receptor and GLP-1 receptor agonism amplifies metabolic benefits in diet-induced obese mice. EMBO Mol Med. 2015;7(3):288\u201398. https:\/\/doi.org\/10.15252\/emmm.201404508.","journal-title":"EMBO Mol Med"},{"issue":"7","key":"2110_CR97","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1002\/oby.24305","volume":"33","author":"P Thornton","year":"2025","unstructured":"Thornton P, Reader V, Digby Z, et al. The NLRP3 inhibitor NT-0796 enhances and sustains GLP-1R agonist-mediated weight loss in a murine diet-induced obesity model. Obes (Silver Spring). 2025;33(7):1309\u201321. https:\/\/doi.org\/10.1002\/oby.24305.","journal-title":"Obes (Silver Spring)"},{"issue":"7631","key":"2110_CR98","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1136\/bmj.39385.347049.80","volume":"335","author":"G Williams","year":"2007","unstructured":"Williams G. Orlistat over the counter. BMJ. 2007;335(7631):1163\u20134. https:\/\/doi.org\/10.1136\/bmj.39385.347049.80.","journal-title":"BMJ"},{"issue":"3","key":"2110_CR99","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1592\/phco.20.4.270.34882","volume":"20","author":"AM Heck","year":"2000","unstructured":"Heck AM, Yanovski JA, Calis KA. Orlistat, a new lipase inhibitor for the management of obesity. Pharmacotherapy. 2000;20(3):270\u20139. https:\/\/doi.org\/10.1592\/phco.20.4.270.34882.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"2110_CR100","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/cpdd.1503","volume":"14","author":"S Gruden","year":"2025","unstructured":"Gruden S, Forslund A, Litorp H, et al. A comparative analysis of the pharmacodynamic and pharmacokinetic properties of 2 controlled-release formulations versus a marketed orlistat product. Clin Pharmacol Drug Dev. 2025;14(4):304\u201310. https:\/\/doi.org\/10.1002\/cpdd.1503.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2110_CR101","doi-asserted-by":"publisher","first-page":"120247","DOI":"10.1016\/j.ijpharm.2021.120247","volume":"596","author":"G Lee","year":"2021","unstructured":"Lee G, Han S, Lu Z, et al. Intestinal delivery in a long-chain fatty acid formulation enables lymphatic transport and systemic exposure of orlistat. Int J Pharm. 2021;596:120247. https:\/\/doi.org\/10.1016\/j.ijpharm.2021.120247.","journal-title":"Int J Pharm"},{"key":"2110_CR102","unstructured":"Bansal AB, Patel P, Al Khalili Y, Orlistat. StatPearls Publishing LLC.; 2025. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31194359"},{"issue":"23","key":"2110_CR103","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1001\/jama.293.23.2873","volume":"293","author":"JP Chanoine","year":"2005","unstructured":"Chanoine JP, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293(23):2873\u201383. https:\/\/doi.org\/10.1001\/jama.293.23.2873.","journal-title":"JAMA"},{"issue":"2","key":"2110_CR104","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3109\/17477166.2010.519387","volume":"6","author":"JP Chanoine","year":"2011","unstructured":"Chanoine JP, Richard M. Early weight loss and outcome at one year in obese adolescents treated with orlistat or placebo. Int J Pediatr Obes. 2011;6(2):95\u2013101. https:\/\/doi.org\/10.3109\/17477166.2010.519387.","journal-title":"Int J Pediatr Obes"},{"issue":"11","key":"2110_CR105","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1111\/jpc.12252","volume":"49","author":"CC Yu","year":"2013","unstructured":"Yu CC, Li AM, Chan KO, et al. Orlistat improves endothelial function in obese adolescents: a randomised trial. J Paediatr Child Health. 2013;49(11):969\u201375. https:\/\/doi.org\/10.1111\/jpc.12252.","journal-title":"J Paediatr Child Health"},{"issue":"12","key":"2110_CR106","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1007\/s00431-004-1534-6","volume":"163","author":"B Ozkan","year":"2004","unstructured":"Ozkan B, Bereket A, Turan S, et al. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163(12):738\u201341. https:\/\/doi.org\/10.1007\/s00431-004-1534-6.","journal-title":"Eur J Pediatr"},{"issue":"9","key":"2110_CR107","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/s0955-2863(98)00006-0","volume":"9","author":"JB Harp","year":"1998","unstructured":"Harp JB. An assessment of the efficacy and safety of orlistat for the long-term management of obesity. J Nutr Biochem. 1998;9(9):516\u201321. https:\/\/doi.org\/10.1016\/s0955-2863(98)00006-0.","journal-title":"J Nutr Biochem"},{"issue":"2","key":"2110_CR108","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1515\/jpem-2024-0429","volume":"38","author":"L Zhang","year":"2025","unstructured":"Zhang L, Meng C, Zhang F, et al. Effects of orlistat on body mass index and serum lipids in overweight and obese adolescents: a meta-analysis. J Pediatr Endocrinol Metab. 2025;38(2):95\u2013101. https:\/\/doi.org\/10.1515\/jpem-2024-0429.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"2110_CR109","doi-asserted-by":"publisher","first-page":"18","DOI":"10.4158\/EP.12.1.18","volume":"12","author":"D Maahs","year":"2006","unstructured":"Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12(1):18\u201328. https:\/\/doi.org\/10.4158\/EP.12.1.18.","journal-title":"Endocr Pract"},{"issue":"3","key":"2110_CR110","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1590\/S0212-16112011000300004","volume":"26","author":"E Garcia Diaz","year":"2011","unstructured":"Garcia Diaz E, Martin Folgueras T. Systematic review of the clinical efficacy of sibutramine and orlistat in weigth loss, quality of life and its adverse effects in obese adolescents. Nutr Hosp. 2011;26(3):451\u20137. https:\/\/doi.org\/10.1590\/S0212-16112011000300004.","journal-title":"Nutr Hosp"},{"issue":"4","key":"2110_CR111","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.jemermed.2007.10.052","volume":"37","author":"MB Forrester","year":"2009","unstructured":"Forrester MB. Pattern of orlistat exposures in children aged 5 years or less. J Emerg Med. 2009;37(4):396\u20139. https:\/\/doi.org\/10.1016\/j.jemermed.2007.10.052.","journal-title":"J Emerg Med"},{"issue":"6","key":"2110_CR112","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/ijo.2013.162","volume":"38","author":"J van Can","year":"2014","unstructured":"van Can J, Sloth B, Jensen CB, et al. Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults. Int J Obes (Lond). 2014;38(6):784\u201393. https:\/\/doi.org\/10.1038\/ijo.2013.162.","journal-title":"Int J Obes (Lond)"},{"issue":"22","key":"2110_CR113","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly AS, Auerbach P, Barrientos-Perez M, et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N Engl J Med. 2020;382(22):2117\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1916038.","journal-title":"N Engl J Med"},{"issue":"5","key":"2110_CR114","doi-asserted-by":"publisher","first-page":"e12495","DOI":"10.1111\/ijpo.12495","volume":"14","author":"LD Mastrandrea","year":"2019","unstructured":"Mastrandrea LD, Witten L, Carlsson Petri KC, et al. Liraglutide effects in a paediatric (7\u201311 y) population with obesity: A randomized, double-blind, placebo-controlled, short-term trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics. Pediatr Obes. 2019;14(5):e12495. https:\/\/doi.org\/10.1111\/ijpo.12495.","journal-title":"Pediatr Obes"},{"issue":"7","key":"2110_CR115","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMoa1903822","volume":"381","author":"WV Tamborlane","year":"2019","unstructured":"Tamborlane WV, Barrientos-Perez M, Fainberg U, et al. Liraglutide in children and adolescents with type 2 diabetes. N Engl J Med. 2019;381(7):637\u201346. https:\/\/doi.org\/10.1056\/NEJMoa1903822.","journal-title":"N Engl J Med"},{"issue":"12","key":"2110_CR116","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1463-1326.2009.01158.x","volume":"11","author":"J Jendle","year":"2009","unstructured":"Jendle J, Nauck MA, Matthews DR, et al. Weight loss with liraglutide, a once-daily human glucagon-like peptide-1 analogue for type 2 diabetes treatment as monotherapy or added to metformin, is primarily as a result of a reduction in fat tissue. Diabetes Obes Metab. 2009;11(12):1163\u201372. https:\/\/doi.org\/10.1111\/j.1463-1326.2009.01158.x.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2110_CR117","doi-asserted-by":"publisher","first-page":"503856","DOI":"10.1016\/j.anpede.2025.503856","volume":"103","author":"M Ruiz Pons","year":"2025","unstructured":"Ruiz Pons M, Gutierrez Vilar M, Garcia Zurita C, et al. Effectiveness of liraglutide in the treatment of adolescent obesity. Pediatr (Engl Ed). 2025;103(1):503856. https:\/\/doi.org\/10.1016\/j.anpede.2025.503856.","journal-title":"Pediatr (Engl Ed)"},{"key":"2110_CR118","doi-asserted-by":"publisher","first-page":"2723","DOI":"10.2147\/DMSO.S531697","volume":"18","author":"K Hoffmann","year":"2025","unstructured":"Hoffmann K, Michalak M, Paczkowska A. Relative effectiveness and safety of the GLP-1 (glucagon-like peptide 1) Receptor agonists, semaglutide and liraglutide in the treatment of obese type 2 diabetics: a prospective observational cohort study in Poland. Diabetes Metab Syndr Obes. 2025;18:2723\u201338. https:\/\/doi.org\/10.2147\/DMSO.S531697.","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"6","key":"2110_CR119","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1056\/NEJMoa2407379","volume":"392","author":"CK Fox","year":"2025","unstructured":"Fox CK, Barrientos-Perez M, Bomberg EM, et al. Liraglutide for children 6 to <\u200912 years of age with obesity - a randomized trial. N Engl J Med. 2025;392(6):555\u201365. https:\/\/doi.org\/10.1056\/NEJMoa2407379.","journal-title":"N Engl J Med"},{"issue":"2","key":"2110_CR120","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s40200-026-02000-8","volume":"25","author":"AR Bilal","year":"2026","unstructured":"Bilal AR, Sajid M, Arfin SMW, et al. Efficacy and safety of GLP-1RA on cardio-metabolic outcomes in overweight or obese Chinese adults: a systematic review and meta-analysis. J Diabetes Metabolic Disorders. 2026;25(2):186. https:\/\/doi.org\/10.1007\/s40200-026-02000-8.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"2","key":"2110_CR121","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s40200-025-01810-6","volume":"24","author":"K Mani","year":"2025","unstructured":"Mani K. GLP-1 receptor agonists on WHO-EML 2025 list: major breakthrough bounded by persistent challenge. J Diabetes Metabolic Disorders. 2025;24(2):284. https:\/\/doi.org\/10.1007\/s40200-025-01810-6.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"2","key":"2110_CR122","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1007\/s40200-025-01663-z","volume":"24","author":"M Zarei","year":"2025","unstructured":"Zarei M, Sabetkasaei M, Mozafari M, et al. The expanding role of semaglutide: beyond glycemic control. J Diabetes Metabolic Disorders. 2025;24(2):160. https:\/\/doi.org\/10.1007\/s40200-025-01663-z.","journal-title":"J Diabetes Metabolic Disorders"},{"key":"2110_CR123","doi-asserted-by":"publisher","first-page":"155","DOI":"10.3389\/fendo.2019.00155","volume":"10","author":"LB Knudsen","year":"2019","unstructured":"Knudsen LB, Lau J. The discovery and development of liraglutide and semaglutide. Front Endocrinol (Lausanne). 2019;10:155. https:\/\/doi.org\/10.3389\/fendo.2019.00155.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2110_CR124","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","volume":"46","author":"MS Capehorn","year":"2020","unstructured":"Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of once-weekly semaglutide 1.0\u00a0mg vs once-daily liraglutide 1.2\u00a0mg as add-on to 1\u20133 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10). Diabetes Metab. 2020;46(2):100\u20139. https:\/\/doi.org\/10.1016\/j.diabet.2019.101117.","journal-title":"Diabetes Metab"},{"issue":"467","key":"2110_CR125","doi-asserted-by":"publisher","first-page":"eaar7047","DOI":"10.1126\/scitranslmed.aar7047","volume":"10","author":"ST Buckley","year":"2018","unstructured":"Buckley ST, Baekdal TA, Vegge A, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. https:\/\/doi.org\/10.1126\/scitranslmed.aar7047","journal-title":"Sci Transl Med"},{"issue":"4","key":"2110_CR126","doi-asserted-by":"publisher","first-page":"e82497","DOI":"10.7759\/cureus.82497","volume":"17","author":"J Karedath","year":"2025","unstructured":"Karedath J, Nall S, Kaur M, et al. Comparative effectiveness and safety of oral versus subcutaneous semaglutide in type 2 diabetes mellitus: a systematic review and meta-analysis. Cureus. 2025;17(4):e82497. https:\/\/doi.org\/10.7759\/cureus.82497.","journal-title":"Cureus"},{"issue":"10403","key":"2110_CR127","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0140-6736(23)01185-6","volume":"402","author":"FK Knop","year":"2023","unstructured":"Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50\u00a0mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;402(10403):705\u201319. https:\/\/doi.org\/10.1016\/S0140-6736(23)01185-6.","journal-title":"Lancet"},{"issue":"24","key":"2110_CR128","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1056\/NEJMoa2208601","volume":"387","author":"D Weghuber","year":"2022","unstructured":"Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med. 2022;387(24):2245\u201357. https:\/\/doi.org\/10.1056\/NEJMoa2208601.","journal-title":"N Engl J Med"},{"issue":"2","key":"2110_CR129","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1007\/s40200-025-01711-8","volume":"24","author":"B Wasilewska","year":"2025","unstructured":"Wasilewska B, Petruczynik A. Semaglutide - properties, action and chromatographic analysis. J Diabetes Metabolic Disorders. 2025;24(2):197. https:\/\/doi.org\/10.1007\/s40200-025-01711-8.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"2","key":"2110_CR130","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1111\/jcpt.13574","volume":"47","author":"A Phillips","year":"2022","unstructured":"Phillips A, Clements JN. Clinical review of subcutaneous semaglutide for obesity. J Clin Pharm Ther. 2022;47(2):184\u201393. https:\/\/doi.org\/10.1111\/jcpt.13574.","journal-title":"J Clin Pharm Ther"},{"key":"2110_CR131","doi-asserted-by":"publisher","first-page":"645563","DOI":"10.3389\/fendo.2021.645563","volume":"12","author":"MM Smits","year":"2021","unstructured":"Smits MM, Van Raalte DH. Safety of semaglutide. Front Endocrinol (Lausanne). 2021;12:645563. https:\/\/doi.org\/10.3389\/fendo.2021.645563.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2110_CR132","doi-asserted-by":"publisher","first-page":"65","DOI":"10.15605\/jafes.037.02.14","volume":"37","author":"HC Tan","year":"2022","unstructured":"Tan HC, Dampil OA, Marquez MM. Efficacy and safety of semaglutide for weight loss in obesity without diabetes: a systematic review and meta-analysis. J ASEAN Fed Endocr Soc. 2022;37(2):65\u201372. https:\/\/doi.org\/10.15605\/jafes.037.02.14.","journal-title":"J ASEAN Fed Endocr Soc"},{"key":"2110_CR133","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.2147\/DDDT.S470826","volume":"18","author":"XD Yang","year":"2024","unstructured":"Yang XD, Yang YY. Clinical pharmacokinetics of semaglutide: a systematic review. Drug Des Devel Ther. 2024;18:2555\u201370. https:\/\/doi.org\/10.2147\/DDDT.S470826.","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"2110_CR134","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","volume":"30","author":"W Wang","year":"2024","unstructured":"Wang W, Volkow ND, Berger NA, et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168\u201376. https:\/\/doi.org\/10.1038\/s41591-023-02672-2.","journal-title":"Nat Med"},{"key":"2110_CR135","doi-asserted-by":"publisher","first-page":"1238353","DOI":"10.3389\/fpsyt.2023.1238353","volume":"14","author":"JR Li","year":"2023","unstructured":"Li JR, Cao J, Wei J, et al. Case Report: Semaglutide-associated depression: a report of two cases. Front Psychiatry. 2023;14:1238353. https:\/\/doi.org\/10.3389\/fpsyt.2023.1238353.","journal-title":"Front Psychiatry"},{"issue":"2","key":"2110_CR136","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s40200-025-01770-x","volume":"24","author":"F Ameer","year":"2025","unstructured":"Ameer F, Villacres NY, Bustos D, et al. Psychological and behavioral effects of GLP-1 and GIP agonists in weight loss: a comprehensive review. J Diabetes Metabolic Disorders. 2025;24(2):253. https:\/\/doi.org\/10.1007\/s40200-025-01770-x.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"1","key":"2110_CR137","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s40200-026-01880-0","volume":"25","author":"A Soliman","year":"2026","unstructured":"Soliman A, Hamour B, Hammad A, et al. Tirzepatide as adjunct therapy in patients with type 1 diabetes: a systematic review and meta-analysis. J Diabetes Metabolic Disorders. 2026;25(1):119. https:\/\/doi.org\/10.1007\/s40200-026-01880-0.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"23","key":"2110_CR138","doi-asserted-by":"publisher","first-page":"14631","DOI":"10.3390\/ijms232314631","volume":"23","author":"I Forzano","year":"2022","unstructured":"Forzano I, Varzideh F, Avvisato R, et al. Tirzepatide: a systematic update. Int J Mol Sci. 2022;23(23):14631. https:\/\/doi.org\/10.3390\/ijms232314631","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2110_CR139","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","volume":"31","author":"RJ Samms","year":"2020","unstructured":"Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410\u201321. https:\/\/doi.org\/10.1016\/j.tem.2020.02.006.","journal-title":"Trends Endocrinol Metab"},{"issue":"13","key":"2110_CR140","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.3390\/molecules27134315","volume":"27","author":"VP Chavda","year":"2022","unstructured":"Chavda VP, Ajabiya J, Teli D, et al. Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review. Molecules. 2022;27(13):4315. https:\/\/doi.org\/10.3390\/molecules27134315","journal-title":"Molecules"},{"key":"2110_CR141","unstructured":"Eli Lilly and Company. Lilly\u2019s Zepbound\u00ae (tirzepatide) superior to Wegovy\u00ae (semaglutide) in head-to-head trial showing an average weight loss of 20.2% vs. 13.7% 2024. Available from: https:\/\/investor.lilly.com\/news-releases\/news-release-details\/lillys-zepboundr-tirzepatide-superior-wegovyr-semaglutide-head"},{"issue":"6","key":"2110_CR142","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.amjmed.2025.01.021","volume":"138","author":"A Moiz","year":"2025","unstructured":"Moiz A, Filion KB, Tsoukas MA, et al. Mechanisms of GLP-1 receptor agonist-induced weight loss: a review of central and peripheral pathways in appetite and energy regulation. Am J Med. 2025;138(6):934\u201340. https:\/\/doi.org\/10.1016\/j.amjmed.2025.01.021.","journal-title":"Am J Med"},{"issue":"1","key":"2110_CR143","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.febslet.2007.11.063","volume":"582","author":"Q Gao","year":"2008","unstructured":"Gao Q, Horvath TL. Neuronal control of energy homeostasis. FEBS Lett. 2008;582(1):132\u2013. https:\/\/doi.org\/10.1016\/j.febslet.2007.11.063. \u200941.","journal-title":"FEBS Lett"},{"issue":"5","key":"2110_CR144","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1007\/s40265-017-0706-4","volume":"77","author":"B Geloneze","year":"2017","unstructured":"Geloneze B, de Lima-Junior JC, Velloso LA. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the brain-adipocyte axis. Drugs. 2017;77(5):493\u2013503. https:\/\/doi.org\/10.1007\/s40265-017-0706-4.","journal-title":"Drugs"},{"key":"2110_CR145","doi-asserted-by":"publisher","first-page":"1431292","DOI":"10.3389\/fendo.2024.1431292","volume":"15","author":"QK Liu","year":"2024","unstructured":"Liu QK. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP\/GLP-1 receptor agonists. Front Endocrinol (Lausanne). 2024;15:1431292. https:\/\/doi.org\/10.3389\/fendo.2024.1431292.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"2110_CR146","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/clinem\/dgae719","volume":"110","author":"RJ Jalleh","year":"2024","unstructured":"Jalleh RJ, Plummer MP, Marathe CS, et al. Clinical consequences of delayed gastric emptying with GLP-1 receptor agonists and tirzepatide. J Clin Endocrinol Metab. 2024;110(1):1\u201315. https:\/\/doi.org\/10.1210\/clinem\/dgae719.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2110_CR147","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/s41591-023-02597-w","volume":"29","author":"TA Wadden","year":"2023","unstructured":"Wadden TA, Chao AM, Machineni S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity: the SURMOUNT-3 phase 3 trial. Nat Med. 2023;29(11):2909\u201318. https:\/\/doi.org\/10.1038\/s41591-023-02597-w.","journal-title":"Nat Med"},{"issue":"7","key":"2110_CR148","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1001\/jama.2024.9217","volume":"332","author":"L Zhao","year":"2024","unstructured":"Zhao L, Cheng Z, Lu Y, et al. Tirzepatide for weight reduction in Chinese adults with obesity: the SURMOUNT-CN randomized clinical trial. JAMA. 2024;332(7):551\u201360. https:\/\/doi.org\/10.1001\/jama.2024.9217.","journal-title":"JAMA"},{"issue":"5","key":"2110_CR149","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1111\/dom.16294","volume":"27","author":"A Zhang","year":"2025","unstructured":"Zhang A, Liu Q, Xiong Y, et al. Tirzepatide reduces body weight by increasing fat utilization via the central nervous system-adipose tissue axis in male mice. Diabetes Obes Metab. 2025;27(5):2844\u201356. https:\/\/doi.org\/10.1111\/dom.16294.","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"2110_CR150","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cmet.2025.03.011","volume":"37","author":"E Ravussin","year":"2025","unstructured":"Ravussin E, Sanchez-Delgado G, Martin CK, et al. Tirzepatide did not impact metabolic adaptation in people with obesity, but increased fat oxidation. Cell Metab. 2025;37(5):1060\u2013e10744. https:\/\/doi.org\/10.1016\/j.cmet.2025.03.011.","journal-title":"Cell Metab"},{"key":"2110_CR151","doi-asserted-by":"publisher","first-page":"1326373","DOI":"10.3389\/fphar.2023.1326373","volume":"14","author":"R Guan","year":"2023","unstructured":"Guan R, Li X, Ma G. Prediction of pediatric dose of tirzepatide from the reference adult dose using physiologically based pharmacokinetic modelling. Front Pharmacol. 2023;14:1326373. https:\/\/doi.org\/10.3389\/fphar.2023.1326373.","journal-title":"Front Pharmacol"},{"key":"2110_CR152","unstructured":"A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2). 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06439277"},{"key":"2110_CR153","doi-asserted-by":"publisher","first-page":"118966","DOI":"10.1016\/j.lfs.2020.118966","volume":"270","author":"X Fang","year":"2021","unstructured":"Fang X, Du Z, Duan C, et al. Beinaglutide shows significantly beneficial effects in diabetes\/obesity-induced nonalcoholic steatohepatitis in ob\/ob mouse model. Life Sci. 2021;270:118966. https:\/\/doi.org\/10.1016\/j.lfs.2020.118966.","journal-title":"Life Sci"},{"key":"2110_CR154","doi-asserted-by":"publisher","first-page":"1433587","DOI":"10.3389\/fphar.2024.1433587","volume":"15","author":"P Lin","year":"2024","unstructured":"Lin P, Li C, Liu Y, et al. Pharmacokinetics and safety profiles of beinaglutide injection, a recombinant human GLP-1, in adults with overweight\/obesity: results from a phase I clinical trial [Clinical Trial]. Front Pharmacol. 2024;15:1433587. https:\/\/doi.org\/10.3389\/fphar.2024.1433587.","journal-title":"Front Pharmacol"},{"issue":"5","key":"2110_CR155","doi-asserted-by":"publisher","first-page":"103244","DOI":"10.4239\/wjd.v16.i5.103244","volume":"16","author":"ABM Kamrul-Hasan","year":"2025","unstructured":"Kamrul-Hasan ABM, Ganakumar V, Nagendra L, et al. Effect of beinaglutide, a thrice-daily GLP-1 receptor agonist, on body weight and metabolic parameters: A systematic review and meta-analysis. World J Diabetes. 2025;16(5):103244. https:\/\/doi.org\/10.4239\/wjd.v16.i5.103244.","journal-title":"World J Diabetes"},{"issue":"2","key":"2110_CR156","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/dom.15360","volume":"26","author":"K Chen","year":"2024","unstructured":"Chen K, Chen L, Shan Z, et al. Beinaglutide for weight management in Chinese individuals with overweight or obesity: a phase 3 randomized controlled clinical study. Diabetes Obes Metab. 2024;26(2):690\u20138. https:\/\/doi.org\/10.1111\/dom.15360.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2110_CR157","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1002\/osp4.342","volume":"5","author":"YL Zhang","year":"2019","unstructured":"Zhang YL, Zhou C, Li XF, et al. Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study. Obes Sci Pract. 2019;5(4):366\u201375. https:\/\/doi.org\/10.1002\/osp4.342.","journal-title":"Obes Sci Pract"},{"issue":"4","key":"2110_CR158","doi-asserted-by":"publisher","first-page":"421","DOI":"10.20945\/2359-3997000000388","volume":"65","author":"G Wang","year":"2021","unstructured":"Wang G, Wu P, Qiu Y, et al. Effect of beinaglutide treatment on weight loss in Chinese patients with type 2 diabetes mellitus and overweight\/obesity. Arch Endocrinol Metab. 2021;65(4):421\u20137. https:\/\/doi.org\/10.20945\/2359-3997000000388.","journal-title":"Arch Endocrinol Metab"},{"issue":"12","key":"2110_CR159","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1345\/aph.1R372","volume":"46","author":"JL Moreno","year":"2012","unstructured":"Moreno JL, Willett KC, Desilets AR. Exenatide as a novel weight loss modality in patients without diabetes. Ann Pharmacother. 2012;46(12):1700\u20136. https:\/\/doi.org\/10.1345\/aph.1R372.","journal-title":"Ann Pharmacother"},{"issue":"5","key":"2110_CR160","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1002\/oby.23395","volume":"30","author":"CK Fox","year":"2022","unstructured":"Fox CK, Clark JM, Rudser KD, et al. Exenatide for weight-loss maintenance in adolescents with severe obesity: a randomized, placebo-controlled trial. Obes (Silver Spring). 2022;30(5):1105\u201315. https:\/\/doi.org\/10.1002\/oby.23395.","journal-title":"Obes (Silver Spring)"},{"key":"2110_CR161","doi-asserted-by":"publisher","first-page":"1290184","DOI":"10.3389\/fphar.2024.1290184","volume":"15","author":"B Chen","year":"2024","unstructured":"Chen B, Zou Z, Zhang X, et al. Exenatide for obesity in children and adolescents: Systematic review and meta-analysis. Front Pharmacol. 2024;15:1290184. https:\/\/doi.org\/10.3389\/fphar.2024.1290184.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2110_CR162","doi-asserted-by":"publisher","first-page":"323","DOI":"10.4274\/jcrpe.galenos.2024.2024-1-5","volume":"16","author":"M Dai","year":"2024","unstructured":"Dai M, Dai S, Gu L, et al. Efficacy of glucagon-like peptide-1 receptor agonists in overweight\/obese and\/or T2DM adolescents: a meta-analysis based on randomized controlled trials. J Clin Res Pediatr Endocrinol. 2024;16(3):323\u201333. https:\/\/doi.org\/10.4274\/jcrpe.galenos.2024.2024-1-5.","journal-title":"J Clin Res Pediatr Endocrinol"},{"issue":"9","key":"2110_CR163","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.1111\/dom.15150","volume":"25","author":"E Pratt","year":"2023","unstructured":"Pratt E, Ma X, Liu R, et al. Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes. Diabetes Obes Metab. 2023;25(9):2642\u20139. https:\/\/doi.org\/10.1111\/dom.15150.","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2110_CR164","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton S, Blevins T, Connery L, et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N Engl J Med. 2023;389(10):877\u201388. https:\/\/doi.org\/10.1056\/NEJMoa2302392.","journal-title":"N Engl J Med"},{"key":"2110_CR165","doi-asserted-by":"publisher","first-page":"155710","DOI":"10.1016\/j.metabol.2023.155710","volume":"149","author":"P Karakasis","year":"2023","unstructured":"Karakasis P, Patoulias D, Pamporis K, et al. Safety and efficacy of the new, oral, small-molecule, GLP-1 receptor agonists orforglipron and danuglipron for the treatment of type 2 diabetes and obesity: systematic review and meta-analysis of randomized controlled trials. Metabolism. 2023;149:155710. https:\/\/doi.org\/10.1016\/j.metabol.2023.155710.","journal-title":"Metabolism"},{"issue":"10","key":"2110_CR166","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1111\/dom.15168","volume":"25","author":"AR Saxena","year":"2023","unstructured":"Saxena AR, Frias JP, Gorman DN, et al. Tolerability, safety and pharmacodynamics of oral, small-molecule glucagon-like peptide-1 receptor agonist danuglipron for type 2 diabetes: A 12-week, randomized, placebo-controlled, Phase 2 study comparing different dose-escalation schemes. Diabetes Obes Metab. 2023;25(10):2805\u201314. https:\/\/doi.org\/10.1111\/dom.15168.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2110_CR167","doi-asserted-by":"publisher","first-page":"8408","DOI":"10.1038\/s41467-024-52353-y","volume":"15","author":"D Zhu","year":"2024","unstructured":"Zhu D, Wang W, Tong G, et al. Efficacy and safety of GLP-1 analog ecnoglutide in adults with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Nat Commun. 2024;15(1):8408. https:\/\/doi.org\/10.1038\/s41467-024-52353-y.","journal-title":"Nat Commun"},{"issue":"1","key":"2110_CR168","doi-asserted-by":"publisher","first-page":"e77089","DOI":"10.7759\/cureus.77089","volume":"17","author":"N Narayan","year":"2025","unstructured":"Narayan N, Vadde T, Sandesara M, et al. Efficacy and safety of efpeglenatide in patients with type 2 diabetes and obesity: a systematic review. Cureus. 2025;17(1):e77089. https:\/\/doi.org\/10.7759\/cureus.77089.","journal-title":"Cureus"},{"issue":"5","key":"2110_CR169","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1111\/dom.16285","volume":"27","author":"Y Liu","year":"2025","unstructured":"Liu Y, Chen W, He X, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of GZR18 in healthy American and Chinese adult subjects. Diabetes Obes Metab. 2025;27(5):2777\u201389. https:\/\/doi.org\/10.1111\/dom.16285.","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"2110_CR170","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1111\/dom.15407","volume":"26","author":"Y Li","year":"2024","unstructured":"Li Y, Cheng Z, Lu W, et al. Efficacy of noiiglutide injection on body weight in obese Chinese adults without diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 2 trial. Diabetes Obes Metab. 2024;26(3):1057\u201368. https:\/\/doi.org\/10.1111\/dom.15407.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2110_CR171","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/CRD.0000000000000513","volume":"32","author":"AM D\u2019Ascanio","year":"2024","unstructured":"D\u2019Ascanio AM, Mullally JA, Frishman WH. Cagrilintide: a long-acting amylin analog for the treatment of obesity. Cardiol Rev. 2024;32(1):83\u201390. https:\/\/doi.org\/10.1097\/CRD.0000000000000513.","journal-title":"Cardiol Rev"},{"issue":"10317","key":"2110_CR172","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/S0140-6736(21)01751-7","volume":"398","author":"DCW Lau","year":"2021","unstructured":"Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160\u201372. https:\/\/doi.org\/10.1016\/S0140-6736(21)01751-7.","journal-title":"Lancet"},{"issue":"1","key":"2110_CR173","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1007\/s40200-026-01942-3","volume":"25","author":"H Rao","year":"2026","unstructured":"Rao H, Kumar S, Ali SME, et al. Cagrilintide and CagriSema for weight reduction and metabolic risk modification in overweight or obesity: a systematic review and meta-analysis. J Diabetes Metabolic Disorders. 2026;25(1):140. https:\/\/doi.org\/10.1007\/s40200-026-01942-3.","journal-title":"J Diabetes Metabolic Disorders"},{"issue":"10286","key":"2110_CR174","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1016\/S0140-6736(21)00845-X","volume":"397","author":"LB Enebo","year":"2021","unstructured":"Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4\u00a0mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021;397(10286):1736\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(21)00845-X.","journal-title":"Lancet"},{"issue":"10403","key":"2110_CR175","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/S0140-6736(23)01163-7","volume":"402","author":"JP Frias","year":"2023","unstructured":"Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2.4\u00a0mg with once-weekly semaglutide 2.4\u00a0mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720\u201330. https:\/\/doi.org\/10.1016\/S0140-6736(23)01163-7.","journal-title":"Lancet"},{"issue":"1","key":"2110_CR176","doi-asserted-by":"publisher","first-page":"8289","DOI":"10.1038\/s41467-023-44067-4","volume":"14","author":"L Ji","year":"2023","unstructured":"Ji L, Jiang H, Cheng Z, et al. A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity. Nat Commun. 2023;14(1):8289. https:\/\/doi.org\/10.1038\/s41467-023-44067-4.","journal-title":"Nat Commun"},{"issue":"1","key":"2110_CR177","doi-asserted-by":"publisher","first-page":"160","DOI":"10.2337\/dc23-1287","volume":"47","author":"B Zhang","year":"2024","unstructured":"Zhang B, Cheng Z, Chen J, et al. Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial. Diabetes Care. 2024;47(1):160\u20138. https:\/\/doi.org\/10.2337\/dc23-1287.","journal-title":"Diabetes Care"},{"issue":"3","key":"2110_CR178","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00125-023-06053-9","volume":"67","author":"M Bluher","year":"2024","unstructured":"Bluher M, Rosenstock J, Hoefler J, et al. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon\/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia. 2024;67(3):470\u201382. https:\/\/doi.org\/10.1007\/s00125-023-06053-9.","journal-title":"Diabetologia"},{"issue":"1","key":"2110_CR179","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1186\/s13098-024-01501-x","volume":"16","author":"H Wan","year":"2024","unstructured":"Wan H, Xu N, Wang L, et al. Effect of survodutide, a glucagon and GLP-1 receptor dual agonist, on weight loss: a meta-analysis of randomized controlled trials. Diabetol Metab Syndr. 2024;16(1):264. https:\/\/doi.org\/10.1186\/s13098-024-01501-x.","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"2110_CR180","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1002\/oby.24184","volume":"33","author":"S Wharton","year":"2025","unstructured":"Wharton S, le Roux CW, Kosiborod MN, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials (SYNCHRONIZE-1 and \u2013\u20092). Obes (Silver Spring). 2025;33(1):67\u201377. https:\/\/doi.org\/10.1002\/oby.24184.","journal-title":"Obes (Silver Spring)"},{"issue":"1","key":"2110_CR181","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","volume":"82","author":"SA Harrison","year":"2025","unstructured":"Harrison SA, Browne SK, Suschak JJ, et al. Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(1):7\u201317. https:\/\/doi.org\/10.1016\/j.jhep.2024.07.006.","journal-title":"J Hepatol"},{"issue":"6","key":"2110_CR182","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.jhep.2024.12.006","volume":"82","author":"L Xiang","year":"2025","unstructured":"Xiang L, Wang G, Zhuang Y, et al. Safety and efficacy of GLP-1\/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study. J Hepatol. 2025;82(6):967\u201378. https:\/\/doi.org\/10.1016\/j.jhep.2024.12.006.","journal-title":"J Hepatol"},{"issue":"3","key":"2110_CR183","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40259-025-00715-3","volume":"39","author":"H Zhang","year":"2025","unstructured":"Zhang H, Li Q, Chen H, et al. First-in-human study on tolerability, pharmacokinetics, and pharmacodynamics of single escalating doses of HEC88473, a novel dual GLP-1 and FGF21 receptor agonist in healthy and obese Chinese subjects. BioDrugs. 2025;39(3):477\u201386. https:\/\/doi.org\/10.1007\/s40259-025-00715-3.","journal-title":"BioDrugs"},{"issue":"2","key":"2110_CR184","doi-asserted-by":"publisher","first-page":"e12432","DOI":"10.1111\/cob.12432","volume":"11","author":"M Alba","year":"2021","unstructured":"Alba M, Yee J, Frustaci ME, et al. Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: A randomized dose-ranging study. Clin Obes. 2021;11(2):e12432. https:\/\/doi.org\/10.1111\/cob.12432.","journal-title":"Clin Obes"},{"issue":"3","key":"2110_CR185","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","volume":"26","author":"MM Jepsen","year":"2021","unstructured":"Jepsen MM, Christensen MB. Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity. Expert Opin Emerg Drugs. 2021;26(3):231\u201343. https:\/\/doi.org\/10.1080\/14728214.2021.1947240.","journal-title":"Expert Opin Emerg Drugs"},{"issue":"4","key":"2110_CR186","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41574-024-00967-z","volume":"20","author":"C Greenhill","year":"2024","unstructured":"Greenhill C. Phase I results for AMG 133. Nat Rev Endocrinol. 2024;20(4):193. https:\/\/doi.org\/10.1038\/s41574-024-00967-z.","journal-title":"Nat Rev Endocrinol"},{"issue":"4","key":"2110_CR187","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1111\/dom.15448","volume":"26","author":"DCD Hope","year":"2024","unstructured":"Hope DCD, Ansari S, Choudhury S, et al. Adaptive infusion of a glucagon-like peptide-1\/glucagon receptor co-agonist G3215, in adults with overweight or obesity: Results from a phase 1 randomized clinical trial. Diabetes Obes Metab. 2024;26(4):1479\u201391. https:\/\/doi.org\/10.1111\/dom.15448.","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2110_CR188","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1111\/dom.16203","volume":"27","author":"Y Fan","year":"2025","unstructured":"Fan Y, Yuan J, Dong L, et al. The safety, tolerability, pharmacokinetics and pharmacodynamics of an optimized dual GLP-1\/GIP receptor agonist (BGM0504) in healthy volunteers: A dose-escalation Phase I study. Diabetes Obes Metab. 2025;27(4):2110\u20139. https:\/\/doi.org\/10.1111\/dom.16203.","journal-title":"Diabetes Obes Metab"},{"issue":"10401","key":"2110_CR189","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","volume":"402","author":"J Rosenstock","year":"2023","unstructured":"Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529\u201344. https:\/\/doi.org\/10.1016\/S0140-6736(23)01053-X.","journal-title":"Lancet"},{"issue":"6","key":"2110_CR190","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa2301972","volume":"389","author":"AM Jastreboff","year":"2023","unstructured":"Jastreboff AM, Kaplan LM, Frias JP, et al. Triple-hormone-receptor agonist retatrutide for obesity - a phase 2 trial. N Engl J Med. 2023;389(6):514\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2301972.","journal-title":"N Engl J Med"},{"issue":"7","key":"2110_CR191","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","volume":"30","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Kaplan LM, Frias JP, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(7):2037\u201348. https:\/\/doi.org\/10.1038\/s41591-024-03018-2.","journal-title":"Nat Med"},{"issue":"1","key":"2110_CR192","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/s40262-013-0104-3","volume":"53","author":"S Kasichayanula","year":"2014","unstructured":"Kasichayanula S, Liu X, Lacreta F, et al. Clinical pharmacokinetics and pharmacodynamics of dapagliflozin, a selective inhibitor of sodium-glucose co-transporter type 2. Clin Pharmacokinet. 2014;53(1):17\u201327. https:\/\/doi.org\/10.1007\/s40262-013-0104-3.","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"2110_CR193","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","volume":"79","author":"MJ Pereira","year":"2019","unstructured":"Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219\u201330. https:\/\/doi.org\/10.1007\/s40265-019-1057-0.","journal-title":"Drugs"},{"key":"2110_CR194","doi-asserted-by":"publisher","first-page":"706914","DOI":"10.3389\/fendo.2021.706914","volume":"12","author":"H Zheng","year":"2021","unstructured":"Zheng H, Liu M, Li S, et al. Sodium-glucose co-transporter-2 inhibitors in non-diabetic adults with overweight or obesity: a systematic review and meta-analysis [systematic review]. Front Endocrinol (Lausanne). 2021;12:706914. https:\/\/doi.org\/10.3389\/fendo.2021.706914.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"2110_CR195","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/oby.20663","volume":"22","author":"HE Bays","year":"2014","unstructured":"Bays HE, Weinstein R, Law G, et al. Canagliflozin: effects in overweight and obese subjects without diabetes mellitus. Obes (Silver Spring). 2014;22(4):1042\u20139. https:\/\/doi.org\/10.1002\/oby.20663.","journal-title":"Obes (Silver Spring)"},{"issue":"5","key":"2110_CR196","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/oby.22764","volume":"28","author":"HE Bays","year":"2020","unstructured":"Bays HE, Kozlovski P, Shao Q, et al. Licogliflozin, a novel SGLT1 and 2 inhibitor: body weight effects in a randomized trial in adults with overweight or obesity. Obes (Silver Spring). 2020;28(5):870\u201381. https:\/\/doi.org\/10.1002\/oby.22764.","journal-title":"Obes (Silver Spring)"},{"issue":"5","key":"2110_CR197","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2337\/dc16-2427","volume":"40","author":"P Hollander","year":"2017","unstructured":"Hollander P, Bays HE, Rosenstock J, et al. Coadministration of canagliflozin and phentermine for weight management in overweight and obese individuals without diabetes: a randomized clinical trial. Diabetes Care. 2017;40(5):632\u20139. https:\/\/doi.org\/10.2337\/dc16-2427.","journal-title":"Diabetes Care"},{"issue":"1","key":"2110_CR198","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1111\/dom.12779","volume":"19","author":"P Lundkvist","year":"2017","unstructured":"Lundkvist P, Sjostrom CD, Amini S, et al. Dapagliflozin once-daily and exenatide once-weekly dual therapy: A 24-week randomized, placebo-controlled, phase II study examining effects on body weight and prediabetes in obese adults without diabetes. Diabetes Obes Metab. 2017;19(1):49\u201360. https:\/\/doi.org\/10.1111\/dom.12779.","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2110_CR199","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40262-022-01189-0","volume":"62","author":"O Petricoul","year":"2023","unstructured":"Petricoul O, Nazarian A, Schuehly U, et al. Pharmacokinetics and pharmacodynamics of bimagrumab (BYM338). Clin Pharmacokinet. 2023;62(1):141\u201355. https:\/\/doi.org\/10.1007\/s40262-022-01189-0.","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"2110_CR200","doi-asserted-by":"publisher","first-page":"e2033457","DOI":"10.1001\/jamanetworkopen.2020.33457","volume":"4","author":"SB Heymsfield","year":"2021","unstructured":"Heymsfield SB, Coleman LA, Miller R, et al. Effect of bimagrumab vs placebo on body fat mass among adults with type 2 diabetes and obesity: a phase 2 randomized clinical trial. JAMA Netw Open. 2021;4(1):e2033457. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.33457.","journal-title":"JAMA Netw Open"},{"issue":"2","key":"2110_CR201","doi-asserted-by":"publisher","first-page":"e0314787","DOI":"10.1371\/journal.pone.0314787","volume":"20","author":"S Yang","year":"2025","unstructured":"Yang S, Xin S, Ju R, et al. Pharmacological interventions for addressing pediatric and adolescent obesity: a systematic review and network meta-analysis. PLoS ONE. 2025;20(2):e0314787. https:\/\/doi.org\/10.1371\/journal.pone.0314787.","journal-title":"PLoS ONE"},{"issue":"23","key":"2110_CR202","doi-asserted-by":"publisher","first-page":"2427","DOI":"10.1001\/jama.2017.0332","volume":"317","author":"EA O\u2019Connor","year":"2017","unstructured":"O\u2019Connor EA, Evans CV, Burda BU, et al. Screening for obesity and intervention for weight management in children and adolescents: evidence report and systematic review for the US preventive services task force. JAMA. 2017;317(23):2427\u201344. https:\/\/doi.org\/10.1001\/jama.2017.0332.","journal-title":"JAMA"},{"issue":"3","key":"2110_CR203","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1038\/s41366-024-01465-y","volume":"49","author":"CK Fox","year":"2025","unstructured":"Fox CK, Kelly AS, Reilly JL, et al. Current and future state of pharmacological management of pediatric obesity. Int J Obes (Lond). 2025;49(3):388\u201396. https:\/\/doi.org\/10.1038\/s41366-024-01465-y.","journal-title":"Int J Obes (Lond)"},{"issue":"17","key":"2110_CR204","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa1105816","volume":"365","author":"P Sumithran","year":"2011","unstructured":"Sumithran P, Prendergast LA, Delbridge E, et al. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011;365(17):1597\u2013604. https:\/\/doi.org\/10.1056\/NEJMoa1105816.","journal-title":"N Engl J Med"},{"issue":"7","key":"2110_CR205","doi-asserted-by":"publisher","first-page":"109045","DOI":"10.1016\/j.jdiacomp.2025.109045","volume":"39","author":"M Ibrahim","year":"2025","unstructured":"Ibrahim M, Ba-Essa EM, Alvarez JA, et al. Obesity and its management in primary care setting. J Diabetes Complications. 2025;39(7):109045. https:\/\/doi.org\/10.1016\/j.jdiacomp.2025.109045.","journal-title":"J Diabetes Complications"}],"container-title":["Journal of Diabetes &amp; Metabolic Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-026-02110-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40200-026-02110-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40200-026-02110-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T05:03:30Z","timestamp":1791867810000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40200-026-02110-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,12]]},"references-count":205,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2110"],"URL":"https:\/\/doi.org\/10.1007\/s40200-026-02110-3","relation":{},"ISSN":["2251-6581"],"issn-type":[{"value":"2251-6581","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,12]]},"assertion":[{"value":"11 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Generative AI was used to improve the grammar and language of the manuscript only. After using this tool\/service, the author(s) reviewed and edited the content as needed and take(s) full responsibility for the content of the publication.","order":5,"name":"Ethics","label":"Declaration of generative AI","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"289"}}